99 mTc-FAPI SPECT/CT for Evaluation of Myocardial Fibrosis and Cardiac Function in Valvular Heart Disease

Yu Zhang, Tian Yue, Guodong Guo, Haotian Zheng, Rongdong Xiao, Qi Xie, Yuanxiang Chen, Wenxin Chen, Chenshen HuangmedRxiv 2025 · DOI

This study, recently published as a preprint, explores a more accessible way to "see" the active process of heart scarring in patients with Valvular Heart Disease (VHD). By using a common nuclear medicine technique (SPECT/CT) paired with a novel tracer ($^{99m}$Tc-FAPI), researchers were able to quantify active fibrosis and monitor how patients responded to treatment, potentially offering a more sensitive "early warning system" than traditional imaging.

TL;DR

Researchers successfully used $^{99m}$Tc-FAPI SPECT/CT to visualize active fibroblast activation—the precursor to permanent scarring—in patients with Valvular Heart Disease. The study found that this molecular imaging technique strongly correlates with disease severity and can detect therapeutic recovery months before structural changes appear on an ultrasound.

What Problem Does This Paper Address?

Valvular Heart Disease (VHD) forces the heart to work under constant pressure or volume overload. To cope, the heart undergoes "remodeling," which involves myocardial fibrosis (scarring). Once fibrosis is established, it is often irreversible and leads to heart failure and arrhythmias.

The current "gold standard" for imaging fibrosis is Cardiac MRI with Late Gadolinium Enhancement (LGE). However, LGE primarily detects replacement fibrosis—essentially, tissue that is already dead or permanently scarred. It struggles to capture the active process of fibroblast activation. While PET/CT imaging using FAPI (Fibroblast Activation Protein Inhibitor) tracers can see this activity, PET is expensive, requires a cyclotron or expensive generators, and isn't available in many hospitals. This paper investigates whether SPECT/CT—a much cheaper and more widely available technology—can do the job using a $^{99m}$Tc-labeled tracer.

Methods

The researchers conducted a prospective study of 30 VHD patients.

  • The Tracer: They used $^{99m}$Tc-HOFAP2. The choice of Technetium-99m ($^{99m}$Tc) is critical because it has a longer half-life than PET isotopes and can be produced easily via standard hospital generators.
  • Imaging: Patients underwent SPECT/CT one hour after injection.
  • Quantification: The team measured the Maximum Standardized Uptake Value (SUVmax), Mean SUV (SUVmean), and "Extent" (the percentage of the heart muscle showing active FAPI uptake).
  • Comparison: These imaging metrics were correlated against clinical benchmarks: echocardiography (ultrasound), blood biomarkers (like troponin), and disease staging (NYHA class and VHD stages).
  • Follow-up: 13 patients were re-scanned three months after treatment (e.g., valve replacement surgery) to see if the "active scarring" had stopped.

Datasets

The study utilized a primary clinical dataset of 30 patients diagnosed with VHD at Fujian Provincial Hospital between January and October 2024.

  • FAPI-positive group: 24 patients.
  • FAPI-negative group: 6 patients.
  • Follow-up cohort: 13 FAPI-positive patients who completed a 3-month post-treatment evaluation.

Key Insights and Ideas

  • Molecular Activity vs. Physical Structure: The most striking insight was that after surgery, FAPI uptake (the molecular signal of scarring) dropped significantly, and heart function (LVEF) improved. However, the physical size of the heart chambers (structural parameters) remained unchanged. This suggests that molecular imaging is a "leading indicator" of recovery, showing healing at the cellular level before the heart physically shrinks back to normal size.
  • The Arrhythmia Link: FAPI-positive patients had a significantly higher prevalence of atrial fibrillation (54.2% vs 0%). This reinforces the idea that active fibroblast activation creates the electrical "noise" that triggers irregular heartbeats.
  • Democratizing Molecular Imaging: By proving that SPECT/CT (the "workhorse" of nuclear medicine) can perform FAPI imaging effectively, the authors open the door for high-end molecular assessment in less-developed regions or smaller clinical centers that lack PET facilities.

Key Results

  • Strong Correlations: FAPI uptake (SUVmax) showed a robust correlation with cardiac troponin I ($r=0.831, p<0.001$), a marker of heart muscle injury.
  • Disease Staging: The "Extent" of FAPI uptake was highly correlated with VHD staging ($\rho=0.849, p<0.001$), meaning the more advanced the disease, the more widespread the active fibrosis.
  • Treatment Response: In the follow-up group, SUVmax decreased from an average of 2.8 to 1.9 ($p<0.0001$), and SUVmean dropped from 2.3 to 1.6 ($p<0.0001$).
  • Functional Recovery: This decrease in active fibrosis was accompanied by an improvement in Left Ventricular Ejection Fraction (LVEF) from 45.3% to 52.1%.

Limitations and Future Work

The authors acknowledge several hurdles:

  1. Sample Size: With only 30 patients, the study is a "proof of concept." Larger, multi-center trials are needed to validate these findings.
  2. Resolution: SPECT has inherently lower spatial resolution than PET, which might make it harder to detect very small or subtle areas of activation.
  3. Duration: The 3-month follow-up is relatively short. Long-term studies are required to see if FAPI-positive patients have worse outcomes (like mortality or heart failure hospitalizations) years down the line.
  4. No Head-to-Head: The study did not directly compare SPECT/CT results with PET/CT or Cardiac MRI in the same patients.

Summary updated

Abstract

Abstract Background Active myocardial fibrosis plays a pivotal role in valvular heart disease (VHD) progression. While conventional imaging modalities primarily detect established fibrosis, the detection of active fibroblast activation remains challenging. 99 mTc-FAPI SPECT/CT, offering advantages of wider availability and lower cost compared to PET imaging, represents a promising tool for evaluating active myocardial fibrosis. Methods We conducted a prospective study of 30 VHD patients who underwent 99 mTc-FAPI SPECT/CT imaging with comprehensive clinical evaluation. Patients were categorized into FAPI-positive (n=24) and FAPI-negative (n=6) groups based on myocardial tracer uptake patterns. Thirteen FAPI-positive patients completed a three-month follow-up to assess therapeutic response. Results FAPI uptake parameters showed robust correlations with established myocardial injury markers (Hs-cTnI vs SUVmax: r=0.831, p&lt;0.001; vs SUVmean: r=0.795, p&lt;0.001) and disease severity indices (VHD staging: r=0.812, p&lt;0.001). FAPI-positive patients demonstrated significantly higher atrial fibrillation prevalence (54.2% vs 0%, P=0.024). Post-treatment follow-up revealed significant improvements in FAPI parameters (SUVmax: 2.8±0.4 to 1.9±0.3, p&lt;0.0001; SUVmean: 2.3±0.3 to 1.6±0.2, p&lt;0.0001), accompanied by enhanced left ventricular ejection fraction (45.3±5.2% to 52.1±4.8%, p=0.0176) and NYHA functional status (p=0.0011), despite unchanged structural parameters. Conclusions This study demonstrates that 99 mTc-FAPI SPECT/CT enables non-invasive visualization and quantification of active myocardial fibrosis in VHD patients. The strong associations between FAPI parameters and clinical indices, coupled with its ability to monitor therapeutic response, suggest its potential as a valuable tool for risk stratification and treatment optimization in VHD management. Trial registration ChiCTR2400094867. Registered 30 December 2024. Public site: https://www.chictr.org.cn/index.html .
BibTeX
@misc{zhang2025sup,
  author = {Yu Zhang and Tian Yue and Guodong Guo and Haotian Zheng and Rongdong Xiao and Qi Xie and Yuanxiang Chen and Wenxin Chen and Chenshen Huang},
  title = {{<sup>99</sup> mTc-FAPI SPECT/CT for Evaluation of Myocardial Fibrosis and Cardiac Function in Valvular Heart Disease}},
  year = {2025},
  doi = {10.1101/2025.04.17.25326016},
  howpublished = {medRxiv},
}

Loading related content...

Figure